152 related articles for article (PubMed ID: 23448725)
21. Identification of epidermal growth factor receptor mutations in pulmonary adenocarcinoma using dual-energy spectral computed tomography.
Li M; Zhang L; Tang W; Jin YJ; Qi LL; Wu N
Eur Radiol; 2019 Jun; 29(6):2989-2997. PubMed ID: 30367185
[TBL] [Abstract][Full Text] [Related]
22. Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection.
Kim H; Chae KJ; Yoon SH; Kim M; Keam B; Kim TM; Kim DW; Goo JM; Park CM
Eur Radiol; 2018 Feb; 28(2):861-868. PubMed ID: 28786010
[TBL] [Abstract][Full Text] [Related]
23. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
Guan J; Xiao NJ; Chen M; Zhou WL; Zhang YW; Wang S; Dai YM; Li L; Zhang Y; Li QY; Li XZ; Yang M; Wu HB; Chen LH; Liu LY
Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
[TBL] [Abstract][Full Text] [Related]
24. EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky.
Larson KL; Huang B; Chen Q; Tucker T; Schuh M; Arnold SM; Kolesar JM
PLoS One; 2020; 15(8):e0237790. PubMed ID: 32810185
[TBL] [Abstract][Full Text] [Related]
25. The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas.
Cho J; Choi SM; Lee J; Lee CH; Lee SM; Yim JJ; Chung DH; Yoo CG; Kim YW; Han SK; Park YS
PLoS One; 2016; 11(11):e0166821. PubMed ID: 27861565
[TBL] [Abstract][Full Text] [Related]
26. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
Pasello G; Vicario G; Zustovich F; Oniga F; Gori S; Rosetti F; Bonetti A; Favaretto A; Toso S; Redelotti R; Santo A; Bernardi D; Giovanis P; Oliani C; Calvetti L; Gatti C; Palazzolo G; Baretta Z; Bortolami A; Bonanno L; Basso M; Menis J; Corte DD; Frega S; Guarneri V; Conte P;
Oncologist; 2019 Jun; 24(6):e318-e326. PubMed ID: 30846513
[TBL] [Abstract][Full Text] [Related]
27. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
Huang CT; Yen RF; Cheng MF; Hsu YC; Wei PF; Tsai YJ; Tsai MF; Shih JY; Yang CH; Yang PC
Med Oncol; 2010 Mar; 27(1):9-15. PubMed ID: 19130320
[TBL] [Abstract][Full Text] [Related]
28. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
[TBL] [Abstract][Full Text] [Related]
29.
Palacio S; Pontes L; Prado E; Arshad J; Ali R; Piha T; Bacchi CE; Mudad R; Lopes G
Oncologist; 2019 Apr; 24(4):e137-e141. PubMed ID: 30446583
[TBL] [Abstract][Full Text] [Related]
30. Gender-based impact of epidermal growth factor receptor mutation in patients with nonsmall cell lung cancer and previous tuberculosis.
Chang CH; Lee CH; Ho CC; Wang JY; Yu CJ
Medicine (Baltimore); 2015 Jan; 94(4):e444. PubMed ID: 25634180
[TBL] [Abstract][Full Text] [Related]
31. Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research.
Esmail LC; Roth J; Rangarao S; Carlson JJ; Thariani R; Ramsey SD; Veenstra DL; Deverka P
Genet Med; 2013 Feb; 15(2):115-22. PubMed ID: 23037935
[TBL] [Abstract][Full Text] [Related]
32. KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings.
Webster J; Kauffman TL; Feigelson HS; Pawloski PA; Onitilo AA; Potosky AL; Cross D; Meier PR; Mirabedi AS; Delate T; Daida Y; Williams AE; Alexander GL; McCarty CA; Honda S; Kushi LH; Goddard KA;
Cancer Epidemiol Biomarkers Prev; 2013 Jan; 22(1):91-101. PubMed ID: 23155138
[TBL] [Abstract][Full Text] [Related]
33. Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.
Hong SJ; Kim TJ; Choi YW; Park JS; Chung JH; Lee KW
Eur Radiol; 2016 Oct; 26(10):3660-8. PubMed ID: 26787602
[TBL] [Abstract][Full Text] [Related]
34. Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.
O'Donnell P; Ferguson J; Shyu J; Current R; Rehage T; Tsai J; Christensen M; Tran HB; Chien SS; Shieh F; Wei W; Lawrence HJ; Wu L; Schilling R; Bloom K; Maltzman W; Anderson S; Soviero S
BMC Cancer; 2013 Apr; 13():210. PubMed ID: 23621958
[TBL] [Abstract][Full Text] [Related]
35. [Value of (18)F-FDG PET-CT imaging to predict epidermal growth factor receptor mutations in patients with lung squamous cell carcinoma].
Zhao CY; Deng XY; Wang HS; Cao GP; Ding JN; Ding CY
Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):795-800. PubMed ID: 34289575
[No Abstract] [Full Text] [Related]
36. Multicenter study of diagnostic procedures, genetic aberration analysis, and first-line treatment of lung cancer in Jiangsu Province, China.
Hu Y; Hu H; Miao L; Zhao X; Gu W; Heng W; Meng Z; Feng J; You Y; Xu X; Hu R; Li H; Zhao J; Zhu X; Shi M; Shen L; Zhang X; Yin X; Ma H; Shi M; Yu Y; Lv H; Cai L; Feng G; Zhang Y; Wu F; Lv T; Song Y
Thorac Cancer; 2018 Mar; 9(3):376-383. PubMed ID: 29341459
[TBL] [Abstract][Full Text] [Related]
37. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
38. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
Ding CY; Yang WP; Guo Z; Sun J; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):528-531. PubMed ID: 28728300
[No Abstract] [Full Text] [Related]
39. Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand.
Tin Tin S; McKeage MJ; Khwaounjoo P; Thi AM; Elwood JM
Cancer Epidemiol; 2018 Dec; 57():24-32. PubMed ID: 30278336
[TBL] [Abstract][Full Text] [Related]
40. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
Villa C; Cagle PT; Johnson M; Patel JD; Yeldandi AV; Raj R; DeCamp MM; Raparia K
Arch Pathol Lab Med; 2014 Oct; 138(10):1353-7. PubMed ID: 24571650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
